On October 28, 2025 Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR artificial intelligence platform to transform oncology drug discovery and development, reported the presentation of clinical data from its ongoing Phase 1 trial of LP-284 at the 25th Annual Lymphoma, Leukemia & Myeloma (LL&M) Congress, held October 14-17, 2025, in New York City. The presentation featured a confirmed complete metabolic response in a 41-year-old patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL) who experienced rapid disease progression following four prior treatment regimens, including CAR-T cell therapy and bispecific antibody therapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The patient achieved complete metabolic response with non-avid lesions after just two 28-day cycles of LP-284, administered intravenously on days 1, 8, and 15 of each cycle. At study entry, the patient presented with extensive multifocal bony lesions following treatment failure with R-CHOP chemotherapy, radiation therapy, a CD19 CAR-T, and a CD3xCD20 bispecific antibody. This clinical outcome validates LP-284’s synthetic lethal mechanism and addresses the critical gap for patients who have exhausted advanced targeted and immunotherapies.
Strategic Inflection Point: Clinical Validation Drives Partnership Momentum
"The presentation of LP-284’s clinical data at the 25th Annual LL&M Congress represents an important inflection point in the development trajectory of this drug-candidate," said Panna Sharma, President and CEO of Lantern Pharma. "Achieving complete metabolic response in a patient who failed both CAR-T and bispecific antibody therapies validates our AI-driven approach towards creating novel cancer medicines at a fraction of the time and cost of traditional approaches, and addresses a critical white space in the post-immunotherapy treatment paradigm. The interest from biopharmaceutical companies and clinical investigators underscores LP-284’s dual strategic potential: as a monotherapy for the growing post-CAR-T, post-bispecific patient population, and as a combination partner with existing FDA-approved agents where we’ve demonstrated compelling preclinical synergy with rituximab."
Strategic Value Proposition for Partnerships
Lantern believes that LP-284’s profile presents compelling partnership opportunities for biopharmaceutical companies seeking to expand their hematology franchises:
Addresses post-immunotherapy treatment gap with novel synthetic lethal mechanism distinct from current standards of care,
Demonstrated preclinical synergy with rituximab in high-grade B-cell lymphoma models, supporting combination therapy development,
Favorable early safety profile with primarily Grade 1-2 adverse events,
Efficacy unaffected by TP53 mutation or lymphoma surface antigen expression—key resistance mechanisms limiting current therapies
Multiple FDA Orphan Drug Designations including in Mantle Cell Lymphoma and High-Grade B-Cell Lymphoma providing regulatory pathway advantages and commercial exclusivity
Strong IP position with composition of matter patents through 2039 across major markets including US, EU, Japan, India, and Mexico
Rapid clinical validation and extension enabled by AI-driven development
These attributes position LP-284 as both a standalone asset for patients who have exhausted CAR-T and bispecific antibody options, and as a potential combination agent to enhance efficacy and duration of response with existing approved therapies.
Addressing Critical Market Need in Post-Immunotherapy Setting
DLBCL represents the most common aggressive non-Hodgkin’s lymphoma subtype, with approximately 200,000 new cases diagnosed globally each year. While initial treatment achieves remission in many patients, those who relapse after advanced immunotherapies face extremely poor prognoses with median survival often measured in months and limited therapeutic alternatives.
The patient featured in the LL&M Congress presentation exemplifies this devastating trajectory: despite achieving initial complete metabolic response with CAR-T therapy at day 30, disease progression occurred by day 90, followed by progressive disease with new lesions after bispecific antibody treatment. With an estimated 40,000 DLBCL patients annually progressing post-CAR-T in the US and EU alone, and average post-relapse treatment costs exceeding $500,000 per patient, LP-284’s off-the-shelf administration and demonstrated activity in this setting could address both clinical and economic burdens commonplace in aggressive blood cancers.
Advancing Development and Strategic Collaborations
Lantern’s ongoing Phase 1a dose-escalation study (NCT06132503) continues to evaluate LP-284’s safety profile and preliminary efficacy in patients with relapsed or refractory B-cell non-Hodgkin’s lymphomas and solid tumors. Initial data demonstrate LP-284 is well tolerated with primarily Grade 1-2 adverse events and validation of the mechanism of action.
Conversations initiated at the LL&M Congress with biopharmaceutical companies and clinical investigators focus on LP-284’s potential in combination regimens with FDA-approved agents, particularly bispecific antibodies and monoclonal antibodies. These discussions leverage Lantern’s RADR platform analysis, which has identified synergistic combination opportunities supported by published preclinical data demonstrating LP-284’s synergy with rituximab.
Near-Term Development Milestones & Potential for Expansion of Indication
Patient follow-up assessment with response durability data expected by year-end 2025
Ongoing partnership discussions for combination therapy trial development
Additional clinical site activation to accelerate enrollment and expand geographic reach
LP-284’s demonstrated selective B-cell depletion activity extends its potential beyond oncology applications. Lantern is advancing preclinical programs targeting autoimmune and inflammatory conditions, representing substantial additional market opportunities in indications focused on inflammation and immune conditions.
Building on Strategic Momentum
This announcement follows the company’s July 2025 disclosure of European Patent Office allowance for LP-284’s composition of matter patent, strengthening global IP protection through early 2039. The expanding international patent portfolio, combined with validated clinical activity and growing partnership interest, positions LP-284 for accelerated development pathways and strategic collaborations that could enhance both development efficiency and commercial potential.
About LP-284
LP-284 is an investigational next-generation acylfulvene designed to exploit synthetic lethal interactions in cancer cells with DNA damage repair deficiencies. Developed through Lantern’s RADR AI platform, LP-284 induces DNA lesions primarily repaired by transcription-coupled nucleotide excision repair (TC-NER), creating a distinct anti-tumor profile. The compound’s efficacy remains unaffected by TP53 mutation or lymphoma surface antigen expression, and preclinical studies demonstrate synergistic activity with rituximab and the ability to overcome ibrutinib resistance. LP-284 is currently in Phase 1 evaluation (NCT06132503) and has received multiple FDA Orphan Drug Designations for mantle cell lymphoma and high-grade B-cell lymphomas.
About the 25th Annual Lymphoma, Leukemia & Myeloma Congress
The Lymphoma, Leukemia & Myeloma Congress is a globally recognized medical education meeting focused exclusively on hematologic malignancies. For 25 years, the Congress has convened international experts to share evidence-based strategies and new drug data. The 2025 Congress, held October 14-17 at the Sheraton New York Times Square Hotel, featured over 75 expert faculty. For more information, visit www.hmpglobalevents.com/llmcongress.
(Press release, Lantern Pharma, OCT 28, 2025, View Source [SID1234657085])